UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549




FORM
8-K





CURRENT
REPORT


Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934




Date of
Report (Date of earliest event reported)February 10,
2009




Progenics
Pharmaceuticals, Inc.


(Exact
name of registrant as specified in its charter)




Delaware
            
            000-23143
            
            13-3379479(State
      or other jurisdiction
              of
      incorporation)
            
            (Commission
              File
      Number)
            
            (IRS
      Employer
              Identification
      No.)777
      Old Saw Mill River Road, Tarrytown, New York
            
            10591(Address
      of principal executive offices)
            
            (Zip
      Code)Registrant's
      telephone number, including area code(914)
      789-2800




Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (seeGeneral
Instruction A.2. below):






oWritten communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




oSoliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))




oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))











Item
8.01. Other Events.





On
February 10, 2009, Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that
it has selected for further development the subcutaneous form of PRO 140 for the
treatment of HIV infection.  The decision follows positive results
from a recently completed phase 2 clinical trial as well as feedback from key
opinion leaders, treatment advocates and people living with HIV. In the clinical
trial, the subcutaneous dosage form of PRO 140 demonstrated potent and highly
significant antiviral effects compared to placebo at all doses of active drug
examined and was generally well tolerated.  Data from the trial
indicate that PRO 140 has the potential to be administered weekly, which may
facilitate its use in conjunction with other antiretroviral
therapies.





PRO 140
is a humanized monoclonal antibody that blocks viral infection of healthy cells
by binding to CCR5, a co-receptor that is the principal molecular portal used by
HIV to enter and infect immune system cells. CCR5 viral-entry inhibitors, such
as PRO 140, are active in blocking infection primarily in HIV patients whose
virus uses the CCR5 portal, but do not block the entry of virus that uses the
CXCR4 co-receptor, which some strains of HIV use as a portal of entry either
exclusively or in addition to CCR5.





A copy of
the press release, including results from the phase 2 study which were presented
at the 16th
Conference on Retroviruses and
Opportunistic Infections(CROI) in Montreal, is attached hereto as
Exhibit 99.1 and the information contained therein is incorporated by reference
into this Item 8.01 of this Current Report on Form 8-K.




Item
9.01   Financial Statements and Exhibits.




(d)
Exhibits





Exhibit
No.     Description




99.1
            Press
      Release dated February 10, 2009.







SIGNATURES






Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.






PROGENICS
PHARMACEUTICALS, INC.


By:/s/ ROBERT A.
MCKINNEY


Robert A. McKinney


Chief Financial Officer, Senior Vice
President,


Finance & Operations and
Treasurer






Date:  February
10, 2009